#United States #Anixa Biosciences #Rochester #CAR-T therapy #Ovarian Cancer

Keynote Presentation on CAR-T Therapy at Ovarian Cancer Conference

Anixa Biosciences, a pioneering biotechnology company, is set to prominently feature its advancements in cancer therapeutics at the upcoming 2026 Ovarian Cancer Midwest Focus Conference. This event, hosted by the esteemed Mayo Clinic and the University of Minnesota, will be held in Rochester, Minnesota, on November 2-3, 2026.

Highlighting Transformative Research

Leading the charge at the conference will be Dr. Jose Conejo-Garcia, MD, PhD, the inventive mind behind Anixa's cutting-edge CAR-T therapy for ovarian cancer. His keynote presentation, titled "Closing in Cracking Ovarian Cancer's Resistance to Immunotherapy," is expected to equip the audience with critical insights into overcoming the challenges faced by current immunotherapy options in treating ovarian cancer. As a Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine, Dr. Conejo-Garcia holds an esteemed position in the field and brings a wealth of knowledge to this pivotal discussion.

Pioneering Cancer Treatments

Anixa’s innovative CAR-T therapy, liraltagene autoleucel (lira-cel), utilizes chimeric endocrine receptor-T (CER-T) cell technology that targets the follicle-stimulating hormone receptor (FSHR), which is prevalent in ovarian cancer cells while minimally expressed in healthy tissues. Currently undergoing a Phase 1 clinical trial with the collaboration of the Moffitt Cancer Center, this investigational therapy aims to evaluate safety, tolerability, and preliminary efficacy across various dosage levels. Encouragingly, the trial reports that no dose-limiting toxicities have been observed, with some patients demonstrating significant survival rates post-treatment, including stability of disease for 90 days in the first patient treated at the highest dose.

The Conference’s Goals and Impact

Designed as a platform for collaboration, the Ovarian Cancer Midwest Focus Conference will unite researchers, clinicians, advocates, and those impacted by ovarian cancer. The conference aims to share groundbreaking research and progress in care methods, bridging various institutions and disciplines. Program highlights will encompass aspects from basic science research to patient perspective discussions, creating a comprehensive view of the current landscape in ovarian cancer research and treatment methodologies.

Anixa Biosciences: Commitment to Innovation

Anixa Biosciences embodies a unique approach in biotechnology by partnering with preeminent research institutions to navigate all stages of therapeutic development. Their current cancer therapeutic portfolio includes additional collaborative efforts with the Cleveland Clinic to develop vaccines targeting breast and ovarian cancers, further emphasizing their commitment to addressing various malignancies, including lung, colon, and prostate cancers.

As the field of cancer treatment evolves, conferences like these not only provide insights into the latest advancements but also create a community for support and knowledge-sharing. Striving for innovative solutions, especially through novel therapies like CAR-T, could redefine the standard of care in ovarian cancer treatment.

For more information, updates, and access to Anixa Biosciences’ ongoing projects, please visit www.anixa.com or follow them on social media platforms including LinkedIn, X, Facebook, and YouTube.

Conclusion

The upcoming conference and Dr. Conejo-Garcia’s keynote address highlight a significant step toward understanding and mitigating ovarian cancer's persistent challenges. With promising research initiatives underway, the hope is not only to improve survival rates but also to enhance the quality of life for patients battling this formidable disease.